Melanocortin and dermal research
Melanotan I
Lyophilized dermal or melanocortin research peptide
Melanotan I / afamelanotide is an alpha-MSH analog research peptide tied to melanocortin receptor and pigment biology literature.
Support can confirm any currently available COAs or batch documentation for this product.
Request available documentsConfirm an optional email signup to receive a single-use 10% welcome code.
Get catalog updatesFor laboratory research use only. Not for human or veterinary use. Not intended to diagnose, treat, cure, mitigate, or prevent disease.
Храните в закрытом, холодном, сухом месте и защищенном от перепадов температур. По прибытии подтвердите хранение конкретного продукта.
Упаковано для обеспечения стабильности транспортировки, поддержка заказов доступна для маршрутов в теплую погоду.
Batch-linked certificate support is available through the documentation desk.
Контекст исследования
Исследовательский профиль Melanotan I
Melanotan I is an alpha-melanocyte-stimulating hormone analog closely associated with the afamelanotide research lineage. It is studied primarily through melanocortin 1 receptor activity, cyclic-AMP signaling, melanogenesis, pigment-cell biology, and photobiology models. Compared with Melanotan II, its research profile is more closely centered on pigment pathways and MC1R rather than broad activity across several melanocortin receptors. It is selected when a study requires an alpha-MSH analog for melanocyte or receptor-selectivity work. Literature on approved afamelanotide products and clinical formulations does not establish the identity, approval, sterility, or intended use of a separate research catalog material.
Предполагаемый механизм
An alpha-MSH analog that activates melanocortin 1 receptors on melanocytes, stimulating adenylate cyclase, cyclic AMP, MITF-related transcription, tyrosinase activity, and eumelanin production.
Эффекты, описанные в исследованиях
- Cell and human afamelanotide studies report increased melanin production and pigmentation-related measures.
- Clinical studies of regulated afamelanotide formulations report improved phototolerance in specific photosensitivity disorders.
- Pigment changes, nevi monitoring, nausea, headache, and formulation-specific adverse events are relevant observations.
Типичные исследовательские конечные точки
MC1R potency, cyclic AMP, MITF, tyrosinase, melanin content, skin reflectance, phototolerance, pigment distribution, nevus changes, pharmacokinetics, and adverse events.
Данные и ограничения
Mechanistic and regulated-product human evidence exists for afamelanotide. Catalog research material is not represented as an approved implant or cosmetic product.
External reading
Literature for context—not product proof.
Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.
Support and documentation
Questions about this product?
What documentation can I request before ordering?
Before ordering, contact support with the product name, selected format, andu2014if availableu2014an order or batch reference to request available batch-linked documentation.
What should I confirm before ordering?
Compare the product name, listed amount, physical form, storage note, price, and documentation route. When the order arrives, match the product and lot or batch reference to the order record and available documentation.